IP Library Granted Patent US 7,495,011
Granted Patent B2
US 7,495,011 · App. 10/564,557 · Granted Feb 24, 2009

Anti-coronavirus drug

Assignee: aRigen Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,495,011
App. No.
10/564,557
Granted
Feb 24, 2009
Kind
B2
Abstract

The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.

Claims (4)

1. A method for treating SARS in a patient in need of treatment using an anti-SARS-associated coronavirus agent comprising as the active ingredient a compound represented by formula (5).

or a pharmaceutically acceptable salt thereof.

2. A method for treating SARS according to claim 1 , wherein the pharmaceutically acceptable salt of the compound represented by formula (5) is a methanesulfonate.

3. A method for treating SARS using an anti-SARS-agent comprising the anti-SARS-associated coronovirus agent according to claim 1 as an active ingredient, and a pharmaceutically acceptable carrier, excipient and/or diluent.

Assignments (2)
CHANGE OF NAME AND ADDRESS Recorded Sep 22, 2008
From: ARIGEN, INC.
To: ARIGEN PHARMACEUTICALS, INC.
Reel/Frame 021565/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2006
From: FUJII, NOBUTAKA; YAMAMOTO, NAOKI
To: ARIGEN, INC.
Reel/Frame 017394/0817 →
Priority Claims (1)
JP 2003-274886 · Jul 15, 2003 · national
Continuity (1)
Related Publication 20060223847A1 · Oct 5, 2006